ABIC-COPD
Discover the ABIC Fund, developed to advance health innovation projects in the area of respiratory diseases, like COPD, for Alberta-based investigators.
Search
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Online application
Online application | FAQ
Internal application
Internal applications | FAQ
Heart Diseases
Heart Diseases
Terms Of Use
TERMS OF USE
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Contact Us
Queries and feedback
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
Legal Notices
Legal Notices
Lung Cancer
Lung Cancer
Corporate profile
Corporate profile
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
Atrial Fibrillation
Atrial Fibrillation
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim - Value Through Innovation
Social media community guidelines
Social media community guidelines
Science Focus
Science and Innovation - Human Health Innovation - Science Focus
Choose the better engineered teat sealant
Choose the better engineered teat sealant
Patient Centricity
Patient Centricity
Engineering & Facilities
Engineering & Facilities
Manufacturing & Supply Chain
Manufacturing & Supply Chain
Gastrointestinal Cancers
Gastrointestinal Cancers
Spark Innovation Challenge
The Type 2 Spark Innovation Challenge encourages innovation, collaboration and change in approaches to addressing T2D in British Columbia. Continue reading.